StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
35
This year
2
Publishing Date
2024 - 02 - 14
1
2024 - 01 - 11
1
2023 - 12 - 11
1
2023 - 10 - 09
1
2023 - 10 - 03
1
2023 - 09 - 27
1
2023 - 03 - 09
1
2023 - 02 - 07
1
2023 - 01 - 31
1
2023 - 01 - 27
1
2023 - 01 - 13
1
2023 - 01 - 03
1
2022 - 12 - 19
1
2022 - 12 - 14
1
2022 - 12 - 09
1
2022 - 11 - 22
1
2022 - 11 - 10
1
2022 - 11 - 08
1
2022 - 10 - 14
1
2022 - 08 - 04
1
2022 - 07 - 21
1
2022 - 06 - 08
1
2022 - 06 - 06
1
2022 - 03 - 17
1
2022 - 02 - 17
1
2021 - 12 - 17
1
2021 - 12 - 10
1
2021 - 08 - 31
1
2021 - 08 - 16
1
2021 - 08 - 13
1
2021 - 08 - 03
1
2021 - 07 - 16
1
2021 - 07 - 05
1
2021 - 05 - 18
1
2021 - 03 - 12
1
Sector
Finance
1
Health services
2
Health technology
35
Manufacturing
1
N/a
3
Tags
Advanced
1
Agreement
1
Alliances
1
Anemia
1
Bat2606
1
Biocanada
1
Biosimilar
3
Biotech-beach
1
Breast cancer
1
Cancer
1
Collaboration
2
Commercialization
1
Corporation
1
Designation
1
Diabetes
1
Diabetic
2
Disease
2
Drug
1
Earnings
3
Education
1
Expected
2
Fda
1
Financial
2
Global
4
Granted
1
Growth
2
Health
1
Her2
1
Her2-
1
Injection
2
Iron deficiency
1
License
1
Lutathera
1
Macular
2
Market
7
Media
1
Melanoma
1
Metastatic breast cancer
1
N/a
18
News
1
Novartis
2
Nucala
1
Ophthalmic emulsion
1
People
6
Pharm-country
1
Pharma
1
Piqray
1
Renal
1
Report
1
Research
5
Results
2
Solutions
1
Study
2
Technology
1
Therapeutics
2
Therapy
1
Treatment
2
Trends
1
Trial
1
Trials
1
Entities
3m company
43
Abb ltd
42
Abbott laboratories
60
Abbvie inc.
59
Albemarle corporation
37
Alnylam pharmaceuticals, inc.
41
Apple inc.
60
Arrival
218
Ballard power systems, inc.
41
Bank of montreal
44
Bausch health companies inc.
37
Biomarin pharmaceutical inc.
39
Black knight, inc.
129
Blackrock, inc.
37
Bristol-myers squibb company
67
Canadian imperial bank of commerce
36
Carecloud inc
41
Cisco systems, inc.
51
Conduent incorporated
79
Cybin inc
49
Duck creek technologies, inc.
52
Eli lilly and company
100
Ericsson
110
Express, inc.
37
Extreme networks, inc.
67
Fat brands inc.
37
Ford motor company
43
Fti consulting, inc.
39
Gartner, inc.
55
General electric company
41
Gilead sciences, inc.
44
Honeywell international inc.
47
Intel corporation
66
International business machines corporation
41
Jaguar health, inc.
78
Johnson & johnson
267
Kering
62
Lithium corp
58
Lpl financial holdings inc.
95
Microsoft corporation
63
Moderna, inc.
51
Morgan stanley
266
Neuronetics, inc.
39
Novo nordisk a/s
37
Omniq corp
48
Oracle corporation
66
Orange
463
Pfizer, inc.
45
Qualcomm incorporated
36
Sanofi
268
Sap se
53
Stmicroelectronics n.v.
40
Takeda pharmaceutical company limited
36
Telus corporation
36
Thermo fisher scientific inc
71
Transunion
50
Twist bioscience corporation
51
Verizon communications inc.
120
Wex inc.
64
X financial
72
Symbols
ABBV
2
ABT
1
ALIM
1
ALKS
1
ALPMF
1
ALPMY
1
ALVO
1
AMGN
4
AMPE
1
AMPED
1
AZN
3
AZNCF
2
BAX
1
BHC
2
BMRN
2
BMY
1
CERS
1
CMXHF
1
CSLLY
1
DTIL
1
DVA
1
DYAI
1
ENDP
1
ENDPQ
1
ERAS
3
FLGT
1
GLAXF
2
GSK
5
INCY
1
INO
1
JNJ
6
KMDA
1
LLY
1
LNTH
1
MDT
2
MNK
1
MNKKQ
1
MNKPF
1
MOR
1
MPSYF
1
MS
1
NBIX
1
NNVC
1
NVO
1
NVS
35
NVSEF
26
PFE
4
PIRS
1
QURE
1
REGN
1
SGEN
1
SNY
7
SNYNF
4
SWTX
1
TAK
2
TEVJF
2
TMO
1
UCBJF
1
UCBJY
1
UTHR
1
Exchanges
Amex
2
Nasdaq
31
Nyse
35
Crawled Date
2024 - 02 - 14
1
2024 - 01 - 11
1
2023 - 12 - 11
1
2023 - 10 - 09
1
2023 - 10 - 03
1
2023 - 09 - 27
1
2023 - 03 - 09
1
2023 - 02 - 07
1
2023 - 01 - 31
1
2023 - 01 - 27
1
2023 - 01 - 13
1
2023 - 01 - 03
1
2022 - 12 - 19
1
2022 - 12 - 14
1
2022 - 12 - 09
1
2022 - 11 - 22
1
2022 - 11 - 10
1
2022 - 11 - 08
1
2022 - 10 - 14
1
2022 - 08 - 04
1
2022 - 07 - 21
1
2022 - 06 - 08
1
2022 - 06 - 06
1
2022 - 03 - 17
1
2022 - 02 - 17
1
2021 - 12 - 17
1
2021 - 12 - 10
1
2021 - 08 - 31
1
2021 - 08 - 16
1
2021 - 08 - 13
1
2021 - 08 - 03
1
2021 - 07 - 16
1
2021 - 07 - 05
1
2021 - 05 - 18
1
2021 - 03 - 12
1
Crawled Time
00:00
45
00:20
10
01:00
47
01:08
1
02:00
25
03:00
34
04:00
23
04:20
8
05:00
23
06:00
69
06:03
2
07:00
39
08:00
34
08:20
4
08:23
1
09:00
45
10:00
33
11:00
52
11:01
1
12:00
83
12:15
6
12:20
16
12:30
9
13:00
35
13:14
1
13:15
7
13:20
8
13:30
5
13:35
1
13:58
1
14:00
50
14:15
2
14:20
10
14:30
7
14:49
1
15:00
55
15:15
4
15:20
16
15:30
16
16:00
56
16:01
1
16:20
4
17:00
65
18:00
55
19:00
45
20:00
48
20:20
3
21:00
34
22:00
55
22:01
1
23:00
44
23:09
1
Source
www.biospace.com
17
www.globenewswire.com
7
www.prnewswire.com
11
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Novartis ag
crawled time :
13:00
save search
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Published:
2024-02-14
(Crawled : 13:00)
- globenewswire.com
ERAS
|
$1.79
0.0%
570K
|
|
7.19%
|
O:
2.99%
H:
2.03%
C:
0.58%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-4.74%
|
O:
-0.02%
H:
0.24%
C:
0.01%
trials
collaboration
trial
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
Published:
2024-01-11
(Crawled : 13:00)
- globenewswire.com
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-12.17%
|
O:
-0.22%
H:
0.43%
C:
0.37%
LNTH
|
$63.8
2.36%
2.3%
800K
|
Health Technology
|
7.62%
|
O:
0.32%
H:
0.03%
C:
-4.42%
lutathera
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
Published:
2023-12-11
(Crawled : 13:00)
- globenewswire.com
ERAS
|
$1.79
0.0%
570K
|
|
-4.28%
|
O:
1.07%
H:
0.0%
C:
-2.65%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-2.01%
|
O:
0.75%
H:
0.55%
C:
0.27%
fda
melanoma
granted
designation
advanced
Dyadic Appoints Doug Pace to Its Executive Leadership Team
Published:
2023-10-09
(Crawled : 13:00)
- globenewswire.com
PFE
A
|
$26.0
2.4%
-0.15%
38M
|
Health Technology
|
-21.52%
|
O:
-0.21%
H:
1.24%
C:
0.42%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-2.86%
|
O:
0.01%
H:
0.47%
C:
0.45%
DYAI
A
|
$1.61
1.26%
1.24%
14K
|
Health Technology
|
-22.06%
|
O:
-2.45%
H:
0.0%
C:
-2.01%
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published:
2023-10-03
(Crawled : 13:00)
- biospace.com/
ALVO
|
News
|
$13.23
2.64%
2.57%
1.7M
|
n/a
|
46.56%
|
O:
2.22%
H:
0.87%
C:
-0.65%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-7.07%
|
O:
-1.6%
H:
0.36%
C:
-0.46%
KMDA
|
News
|
$5.05
-0.98%
-0.99%
27K
|
Health Technology
|
-3.61%
|
O:
0.1%
H:
0.74%
C:
-1.67%
xolair
biosimilar
commercialization
agreement
Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer
Published:
2023-09-27
(Crawled : 13:00)
- biospace.com/
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
11.81%
|
O:
1.99%
H:
0.0%
C:
0.0%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
-6.96%
|
O:
-0.13%
H:
0.06%
C:
-1.02%
CERS
|
$1.675
2.13%
2.09%
980K
|
Health Technology
|
9.09%
|
O:
-1.3%
H:
5.92%
C:
0.66%
corporation
Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines
Published:
2023-03-09
(Crawled : 13:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
33.51%
|
O:
-5.6%
H:
1.19%
C:
1.19%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
13.29%
|
O:
-3.04%
H:
0.16%
C:
-0.9%
global
biosimilar
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Published:
2023-02-07
(Crawled : 13:00)
- biospace.com/
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
35.82%
|
O:
2.27%
H:
0.0%
C:
0.0%
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
|
-16.2%
|
O:
-0.13%
H:
1.01%
C:
0.89%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
10.4%
|
O:
0.29%
H:
0.86%
C:
0.72%
XNCR
|
$18.385
-2.98%
-3.07%
830K
|
Health Technology
|
-49.81%
|
O:
-0.19%
H:
1.15%
C:
-2.27%
MOR
|
News
|
$17.96
-0.5%
-0.5%
180K
|
Health Technology
|
258.88%
|
O:
1.6%
H:
0.0%
C:
-0.59%
INCY
|
$52.3
-0.98%
-0.99%
2.2M
|
Health Technology
|
-37.94%
|
O:
-1.02%
H:
0.29%
C:
-3.04%
financial
Global Precision Medicine Market Competitive Landscape and Trends - By The Business Research Company
Published:
2023-01-31
(Crawled : 13:00)
- prnewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
24.85%
|
O:
-0.75%
H:
0.0%
C:
-1.15%
TMO
|
News
|
$544.78
0.6%
0.0%
1.7M
|
Health Technology
|
-3.46%
|
O:
-0.37%
H:
1.5%
C:
1.45%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
5.27%
|
O:
-0.09%
H:
1.19%
C:
1.18%
MDT
|
$79.48
0.37%
-0.29%
6.7M
|
Health Technology
|
-3.75%
|
O:
0.21%
H:
1.16%
C:
1.14%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-5.45%
|
O:
-0.35%
H:
0.0%
C:
0.0%
research
global
trends
market
Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market
Published:
2023-01-27
(Crawled : 13:00)
- biospace.com/
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
5.03%
|
O:
-0.56%
H:
0.73%
C:
0.17%
market
ophthalmic emulsion
The Worldwide Lysosomal Disease Treatment Industry is Expected to Reach $11 Billion by 2028
Published:
2023-01-13
(Crawled : 13:00)
- prnewswire.com
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-6.69%
|
O:
-0.13%
H:
0.76%
C:
0.76%
AZNCF
|
News
|
$138.24
-4.19%
800
|
Health Technology
|
-1.77%
|
O:
2.77%
H:
0.63%
C:
0.63%
TAK
|
News
|
$13.24
0.61%
0.0%
1.3M
|
Health Technology
|
-15.88%
|
O:
0.13%
H:
2.35%
C:
2.16%
PFE
A
|
$26.0
2.4%
-0.15%
38M
|
Health Technology
|
-45.5%
|
O:
-0.44%
H:
1.39%
C:
0.74%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
4.2%
|
O:
0.15%
H:
0.65%
C:
0.4%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-14.99%
|
O:
-0.47%
H:
0.47%
C:
0.14%
LLY
|
News
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
|
102.25%
|
O:
0.13%
H:
1.04%
C:
0.57%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-4.27%
|
O:
1.89%
H:
0.0%
C:
0.0%
BMRN
|
$88.68
-1.54%
-1.57%
1.8M
|
Health Technology
|
-21.96%
|
O:
-1.16%
H:
2.27%
C:
0.42%
AZN
|
News
|
$68.56
0.29%
0.29%
4.7M
|
Health Technology
|
-2.18%
|
O:
1.27%
H:
0.78%
C:
0.15%
treatment
disease
expected
Outlook on the Pharmaceutical Drugs Global Market to 2027: Look at the Changing Structure of the Pharma and Healthcare Industry
Published:
2023-01-03
(Crawled : 13:00)
- prnewswire.com
ENDPQ
|
$0.0006
-50.0%
3.4K
|
n/a
|
-94.35%
|
O:
-1.13%
H:
28.57%
C:
19.0%
CSLLY
|
$86.918
3.3%
60K
|
n/a
|
-10.99%
|
O:
-3.93%
H:
2.17%
C:
1.75%
MNK
|
$0.3402
-0.06%
540K
|
n/a
|
-94.75%
|
O:
3.1%
H:
0.0%
C:
-2.75%
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
15.53%
|
O:
-0.2%
H:
2.06%
C:
2.06%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-3.71%
|
O:
1.09%
H:
0.54%
C:
0.54%
UCBJY
|
$63.676
-4.38%
7.2K
|
Manufacturing
|
64.2%
|
O:
1.0%
H:
0.0%
C:
-0.26%
ALPMY
|
$9.47
-1.11%
520K
|
Manufacturing
|
-37.34%
|
O:
3.43%
H:
0.0%
C:
-2.93%
VTRS
A
|
$11.25
1.17%
1.16%
4.7M
|
Health Technology
|
1.08%
|
O:
0.54%
H:
2.5%
C:
1.7%
NVO
|
News
|
$122.71
-0.03%
0.17%
5M
|
Health Technology
|
-9.33%
|
O:
1.43%
H:
0.84%
C:
-0.23%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
4.01%
|
O:
0.42%
H:
1.35%
C:
1.22%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-16.27%
|
O:
-0.28%
H:
1.26%
C:
1.15%
GSK
|
News
|
$39.75
1.22%
0.0%
1.6M
|
Health Technology
|
13.12%
|
O:
-0.57%
H:
1.35%
C:
1.0%
BHC
|
$8.69
1.05%
0.0%
2.9M
|
Health Technology
|
38.38%
|
O:
0.48%
H:
3.96%
C:
-0.48%
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
|
2.97%
|
O:
0.27%
H:
0.6%
C:
0.21%
SNY
|
News
|
$46.32
2.05%
2.01%
3.3M
|
Health Technology
|
-4.26%
|
O:
0.16%
H:
0.0%
C:
0.0%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
2.39%
|
O:
-0.67%
H:
0.66%
C:
0.3%
pharma
global
market
Cell Therapy Market Value to Reach US$ 54.6 Bn by 2032, States TMR Study
Published:
2022-12-19
(Crawled : 13:00)
- prnewswire.com
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
4.29%
|
O:
0.0%
H:
0.09%
C:
-0.32%
VCEL
|
$43.74
-0.27%
-0.27%
520K
|
Health Technology
|
78.09%
|
O:
-0.49%
H:
0.02%
C:
-6.55%
therapy
study
market
Outlook on the Age-related Macular Degeneration Global Market to 2030 - Players Include Bayer, Pfizer, Bausch Health and Amgen Among Others
Published:
2022-12-14
(Crawled : 13:00)
- prnewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
23.48%
|
O:
1.74%
H:
0.45%
C:
-1.8%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
3.45%
|
O:
1.0%
H:
1.29%
C:
0.45%
BHC
|
$8.69
1.05%
0.0%
2.9M
|
Health Technology
|
12.71%
|
O:
-0.39%
H:
3.26%
C:
2.34%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
-1.22%
|
O:
-0.11%
H:
0.51%
C:
-0.31%
global
macular
health
market
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Published:
2022-12-09
(Crawled : 13:00)
- globenewswire.com
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
23.48%
|
O:
0.55%
H:
0.39%
C:
0.39%
ERAS
|
$1.79
0.0%
570K
|
|
-75.51%
|
O:
-9.03%
H:
0.75%
C:
-14.59%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
3.04%
|
O:
0.24%
H:
0.32%
C:
-0.93%
license
The Worldwide Diabetic Retinopathy Industry is Expected to Reach $7.7 Billion by 2027 at a 11.3% CAGR
Published:
2022-11-22
(Crawled : 13:00)
- prnewswire.com
PFE
A
|
$26.0
2.4%
-0.15%
38M
|
Health Technology
|
-46.04%
|
O:
0.33%
H:
1.88%
C:
1.53%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
8.72%
|
O:
0.77%
H:
0.41%
C:
0.27%
REGN
|
$896.27
0.26%
0.25%
500K
|
Health Technology
|
21.36%
|
O:
0.66%
H:
0.79%
C:
0.72%
ALIM
|
$3.41
-0.87%
-0.88%
48K
|
Health Technology
|
-21.23%
|
O:
0.47%
H:
7.5%
C:
-1.17%
expected
diabetic
Seagen Names David R. Epstein as Chief Executive Officer and Director
Published:
2022-11-10
(Crawled : 13:00)
- biospace.com/
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
13.73%
|
O:
2.81%
H:
0.43%
C:
-0.2%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
|
65.8%
|
O:
-1.69%
H:
0.1%
C:
-3.37%
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Published:
2022-11-08
(Crawled : 13:00)
- biospace.com/
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
15.34%
|
O:
-0.54%
H:
1.08%
C:
0.57%
SWTX
|
$40.075
-5.64%
-5.98%
1.4M
|
Health Technology
|
77.59%
|
O:
1.64%
H:
4.18%
C:
-1.53%
DTIL
|
$9.75
-9.05%
-9.95%
170K
|
Health Technology
|
685.48%
|
O:
-0.81%
H:
6.5%
C:
3.25%
financial
update
results
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala® (mepolizumab) Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase I cli...
Published:
2022-10-14
(Crawled : 13:00)
- biospace.com/
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
24.14%
|
O:
0.17%
H:
0.8%
C:
-0.75%
MS
|
News
0 d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
|
14.3%
|
O:
-2.63%
H:
2.37%
C:
-2.5%
JNJ
|
News
|
$147.91
1.49%
-0.03%
9.6M
|
Health Technology
|
-8.21%
|
O:
1.93%
H:
0.0%
C:
0.0%
DVA
|
$127.82
1.36%
0.0%
490K
|
Health Services
|
42.82%
|
O:
0.65%
H:
1.88%
C:
-0.77%
VRNA
|
$15.82
-1.74%
-1.83%
640K
|
Health Technology
|
57.2%
|
O:
0.4%
H:
1.39%
C:
-0.3%
UTHR
|
$237.99
0.45%
0.45%
400K
|
Health Technology
|
11.31%
|
O:
0.24%
H:
1.71%
C:
1.01%
NNVC
|
$1.1
-6.38%
0.0%
22K
|
Health Technology
|
-35.67%
|
O:
2.34%
H:
0.0%
C:
0.0%
bat2606
nucala
solutions
biosimilar
study
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
Published:
2022-08-04
(Crawled : 13:00)
- biospace.com/
NVSEF
|
$93.6375
6.88%
82K
|
Health Technology
|
28.56%
|
O:
-2.88%
H:
0.0%
C:
-0.21%
NVS
|
$94.36
1.93%
0.0%
2.3M
|
Health Technology
|
11.19%
|
O:
0.2%
H:
0.44%
C:
0.24%
QURE
|
$4.68
-0.64%
-0.64%
550K
|
Health Technology
|
-81.01%
|
O:
1.32%
H:
1.12%
C:
0.34%
FLGT
|
$20.34
1.14%
1.13%
160K
|
Health Services
|
-67.65%
|
O:
0.43%
H:
3.12%
C:
0.85%
BMRN
|
$88.68
-1.54%
-1.57%
1.8M
|
Health Technology
|
0.26%
|
O:
1.7%
H:
4.68%
C:
3.43%
AMGN
|
$269.03
2.39%
2.33%
3.4M
|
Health Technology
|
8.82%
|
O:
-0.06%
H:
0.81%
C:
-0.01%
← Previous
1
2
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
KUKE
|
$2.88
2.49%
7.64%
360K
|
CXM
4
|
$11.34
-0.44%
4.27%
1.7M
|
Information
RNR
4
|
$224.74
0.85%
3.52%
310K
|
Finance
BSBR
|
$5.25
2.54%
0.38%
430K
|
Finance
JOE
4
|
$54.88
1.22%
0.22%
210K
|
Finance
MUSA
4
|
$417.23
1.06%
0.01%
170K
|
Retail Trade
JBI
4
|
$15.14
1.34%
0.0%
2.9M
|
SBS
|
$15.49
-1.59%
-0.84%
4.6M
|
Utilities
ML
4
|
$69.13
-4.48%
-1.64%
110K
|
SG
4
|
$20.65
-0.91%
-2.14%
1.4M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.